Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Glynn, Sc.D., Ph.D.

Co-Author

This page shows the publications co-authored by Robert Glynn and Sebastian Schneeweiss.
Connection Strength

15.726
  1. Real-World Data Analytics Fit for Regulatory Decision-Making. Am J Law Med. 2018 May; 44(2-3):197-217.
    View in: PubMed
    Score: 0.759
  2. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:138-47.
    View in: PubMed
    Score: 0.501
  3. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007 Oct; 45(10 Supl 2):S131-42.
    View in: PubMed
    Score: 0.364
  4. Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. Am J Manag Care. 2007 Aug; 13(8):445-52.
    View in: PubMed
    Score: 0.360
  5. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007 Apr 24; 115(16):2128-35.
    View in: PubMed
    Score: 0.352
  6. Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med. 2004 May; 19(5 Pt 1):444-50.
    View in: PubMed
    Score: 0.288
  7. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003 Oct; 74(4):388-400.
    View in: PubMed
    Score: 0.276
  8. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003 Aug; 38(4):1103-20.
    View in: PubMed
    Score: 0.273
  9. Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002 Aug; 55(8):833-41.
    View in: PubMed
    Score: 0.255
  10. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2022 03; 24(3):442-454.
    View in: PubMed
    Score: 0.243
  11. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001 Nov 01; 154(9):854-64.
    View in: PubMed
    Score: 0.242
  12. Longitudinal Data Discontinuity in Electronic Health Records and Consequences for Medication Effectiveness Studies. Clin Pharmacol Ther. 2022 01; 111(1):243-251.
    View in: PubMed
    Score: 0.240
  13. Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study. Ann Intern Med. 2021 09; 174(9):1214-1223.
    View in: PubMed
    Score: 0.237
  14. Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. Clin Pharmacol Ther. 2021 04; 109(4):816-828.
    View in: PubMed
    Score: 0.231
  15. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 03 09; 143(10):1002-1013.
    View in: PubMed
    Score: 0.228
  16. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. Clin Pharmacol Ther. 2020 10; 108(4):874-884.
    View in: PubMed
    Score: 0.219
  17. Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. J Gerontol A Biol Sci Med Sci. 2020 05 22; 75(6):1120-1125.
    View in: PubMed
    Score: 0.219
  18. Kim et al. Respond to "Estimation With Claims-Based Frailty Indexes". Am J Epidemiol. 2020 05 05; 189(5):373-374.
    View in: PubMed
    Score: 0.218
  19. Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. Clin Pharmacol Ther. 2020 04; 107(4):735-737.
    View in: PubMed
    Score: 0.215
  20. External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research. Clin Epidemiol. 2020; 12:133-141.
    View in: PubMed
    Score: 0.214
  21. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. Clin Pharmacol Ther. 2020 04; 107(4):817-826.
    View in: PubMed
    Score: 0.210
  22. Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiol Drug Saf. 2019 10; 28(10):1290-1298.
    View in: PubMed
    Score: 0.207
  23. Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. J Gerontol A Biol Sci Med Sci. 2019 07 12; 74(8):1271-1276.
    View in: PubMed
    Score: 0.206
  24. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. Clin Pharmacol Ther. 2019 04; 105(4):867-877.
    View in: PubMed
    Score: 0.201
  25. Comparing Approaches to Measure Frailty in Medicare Data: Deficit-Accumulation Frailty Index Versus Phenotypic Frailty. J Gerontol A Biol Sci Med Sci. 2018 06 14; 73(7):989-990.
    View in: PubMed
    Score: 0.191
  26. Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research. Epidemiology. 2018 05; 29(3):356-363.
    View in: PubMed
    Score: 0.190
  27. Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. Clin Pharmacol Ther. 2018 05; 103(5):899-905.
    View in: PubMed
    Score: 0.183
  28. Prediction Score for Anticoagulation Control Quality Among Older Adults. J Am Heart Assoc. 2017 Oct 05; 6(10).
    View in: PubMed
    Score: 0.182
  29. Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. Epidemiology. 2017 03; 28(2):237-248.
    View in: PubMed
    Score: 0.175
  30. Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. J Clin Epidemiol. 2016 08; 76:200-8.
    View in: PubMed
    Score: 0.163
  31. Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. Am J Epidemiol. 2015 Oct 01; 182(7):651-9.
    View in: PubMed
    Score: 0.157
  32. Evaluating possible confounding by prescriber in comparative effectiveness research. Epidemiology. 2015 Mar; 26(2):238-41.
    View in: PubMed
    Score: 0.152
  33. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17.
    View in: PubMed
    Score: 0.150
  34. Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments. Epidemiology. 2014 Mar; 25(2):268-78.
    View in: PubMed
    Score: 0.142
  35. Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel. Med Decis Making. 2013 10; 33(7):949-60.
    View in: PubMed
    Score: 0.137
  36. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30; 2(4):e000208.
    View in: PubMed
    Score: 0.136
  37. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013 May; 24(3):375-8.
    View in: PubMed
    Score: 0.134
  38. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013 May; 24(3):401-9.
    View in: PubMed
    Score: 0.134
  39. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.130
  40. Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing? Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):e61-4.
    View in: PubMed
    Score: 0.128
  41. Association between the Part D coverage gap and adverse health outcomes. J Am Geriatr Soc. 2012 Aug; 60(8):1408-17.
    View in: PubMed
    Score: 0.127
  42. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012 Jul; 92(1):80-6.
    View in: PubMed
    Score: 0.126
  43. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:69-80.
    View in: PubMed
    Score: 0.125
  44. Beneficiaries with cardiovascular disease and thePart D coverage gap. Circ Cardiovasc Qual Outcomes. 2012 May; 5(3):387-95.
    View in: PubMed
    Score: 0.125
  45. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012 Mar; 23(2):238-46.
    View in: PubMed
    Score: 0.124
  46. Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. J Clin Psychopharmacol. 2012 Feb; 32(1):3-10.
    View in: PubMed
    Score: 0.123
  47. Response to commentary by Marcus and Gibbons. Pharmacoepidemiol Drug Saf. 2012 Jul; 21(7):713.
    View in: PubMed
    Score: 0.123
  48. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012 Jun; 21(6):631-9.
    View in: PubMed
    Score: 0.122
  49. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012 Jul; 21(7):697-709.
    View in: PubMed
    Score: 0.122
  50. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011 Dec; 90(6):777-90.
    View in: PubMed
    Score: 0.121
  51. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011 Dec 01; 174(11):1213-22.
    View in: PubMed
    Score: 0.121
  52. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. PLoS Med. 2011 Aug; 8(8):e1001075.
    View in: PubMed
    Score: 0.119
  53. Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):675-83.
    View in: PubMed
    Score: 0.117
  54. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011 Jun 15; 173(12):1404-13.
    View in: PubMed
    Score: 0.117
  55. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011 Jul; 64(7):749-59.
    View in: PubMed
    Score: 0.114
  56. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010 Dec 13; 170(22):1968-76.
    View in: PubMed
    Score: 0.114
  57. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010 Dec 13; 170(22):1979-86.
    View in: PubMed
    Score: 0.114
  58. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010 Jun; 48(6 Suppl):S114-20.
    View in: PubMed
    Score: 0.110
  59. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1134-42.
    View in: PubMed
    Score: 0.106
  60. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010 Mar; 31(5):561-72.
    View in: PubMed
    Score: 0.106
  61. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009 Jul; 20(4):512-22.
    View in: PubMed
    Score: 0.103
  62. Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications. Med Care. 2009 May; 47(5):508-16.
    View in: PubMed
    Score: 0.102
  63. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009 Dec; 62(12):1226-32.
    View in: PubMed
    Score: 0.101
  64. Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol. 2009 Dec; 62(12):1233-41.
    View in: PubMed
    Score: 0.101
  65. Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther. 2008; 30 Spec No:1038-50.
    View in: PubMed
    Score: 0.093
  66. Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care. 2007 Oct; 45(10 Supl 2):S158-65.
    View in: PubMed
    Score: 0.091
  67. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control. 2007 Jun; 18(5):561-9.
    View in: PubMed
    Score: 0.088
  68. Performance of propensity score calibration--a simulation study. Am J Epidemiol. 2007 May 15; 165(10):1110-8.
    View in: PubMed
    Score: 0.088
  69. Propensity Score Calibration and its Alternatives. Am J Epidemiol. 2007; 165(10):1122-1123.
    View in: PubMed
    Score: 0.086
  70. Propensity Score Calibration and its Alternatives. Am J Epidemiol. 2007; 165(10):1122-1123.
    View in: PubMed
    Score: 0.086
  71. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007 Jan 02; 115(1):27-33.
    View in: PubMed
    Score: 0.086
  72. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
    View in: PubMed
    Score: 0.085
  73. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006 Jun; 28(6):964-78; discussion 962-3.
    View in: PubMed
    Score: 0.083
  74. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006 Aug; 59(8):819-28.
    View in: PubMed
    Score: 0.083
  75. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May; 54(5):1378-89.
    View in: PubMed
    Score: 0.083
  76. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther. 2006 Apr; 79(4):379-88.
    View in: PubMed
    Score: 0.082
  77. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006 Mar; 98(3):253-9.
    View in: PubMed
    Score: 0.082
  78. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006 Jan; 59(1):18-25.
    View in: PubMed
    Score: 0.080
  79. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006 May; 59(5):437-47.
    View in: PubMed
    Score: 0.079
  80. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005 Aug; 62(8):1242-8.
    View in: PubMed
    Score: 0.078
  81. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol. 2005 Aug 01; 162(3):279-89.
    View in: PubMed
    Score: 0.078
  82. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension. 2005 Aug; 46(2):273-9.
    View in: PubMed
    Score: 0.078
  83. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005 May 01; 161(9):891-8.
    View in: PubMed
    Score: 0.077
  84. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005 Jan; 16(1):17-24.
    View in: PubMed
    Score: 0.075
  85. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan; 58(1):98-102.
    View in: PubMed
    Score: 0.075
  86. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ. 2004 Mar 06; 328(7439):560.
    View in: PubMed
    Score: 0.071
  87. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002 Mar 19; 166(6):737-45.
    View in: PubMed
    Score: 0.062
  88. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002 Mar 14; 346(11):822-9.
    View in: PubMed
    Score: 0.062
  89. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiol Drug Saf. 2022 May; 31(5):566-576.
    View in: PubMed
    Score: 0.061
  90. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2022 01; 175(1):W4-W5.
    View in: PubMed
    Score: 0.061
  91. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 11; 174(11):1528-1541.
    View in: PubMed
    Score: 0.060
  92. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021 08; 44(8):1774-1782.
    View in: PubMed
    Score: 0.059
  93. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care. 2021 03; 44(3):826-835.
    View in: PubMed
    Score: 0.057
  94. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020 08 25; 370:m2812.
    View in: PubMed
    Score: 0.056
  95. Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clin Epidemiol. 2020; 12:607-616.
    View in: PubMed
    Score: 0.055
  96. Improving measurement of binary covariates in claims data: A simulation study. Pharmacoepidemiol Drug Saf. 2020 09; 29(9):1093-1100.
    View in: PubMed
    Score: 0.053
  97. Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Saf. 2019 11; 42(11):1355-1363.
    View in: PubMed
    Score: 0.053
  98. Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Wash DC). 2019 Jul 15; 7(1):27.
    View in: PubMed
    Score: 0.052
  99. A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. Clin Pharmacol Ther. 2019 07; 106(1):238-244.
    View in: PubMed
    Score: 0.050
  100. The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation. Epidemiology. 2019 03; 30(2):204-211.
    View in: PubMed
    Score: 0.050
  101. Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. Pharmacoepidemiol Drug Saf. 2019 05; 28(5):665-670.
    View in: PubMed
    Score: 0.050
  102. Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004684.
    View in: PubMed
    Score: 0.048
  103. Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. J Gerontol A Biol Sci Med Sci. 2018 06 14; 73(7):980-987.
    View in: PubMed
    Score: 0.048
  104. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
    View in: PubMed
    Score: 0.047
  105. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018 02 06; 360:k119.
    View in: PubMed
    Score: 0.047
  106. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.
    View in: PubMed
    Score: 0.047
  107. Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Aff (Millwood). 2018 01; 37(1):125-133.
    View in: PubMed
    Score: 0.046
  108. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. J Comp Eff Res. 2018 01; 7(1):57-66.
    View in: PubMed
    Score: 0.046
  109. Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Saf. 2017 10; 40(10):923-932.
    View in: PubMed
    Score: 0.046
  110. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.
    View in: PubMed
    Score: 0.041
  111. Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerg Themes Epidemiol. 2016; 13:5.
    View in: PubMed
    Score: 0.041
  112. Developing alerting thresholds for prospective drug safety monitoring. Pharmacoepidemiol Drug Saf. 2016 07; 25(7):755-62.
    View in: PubMed
    Score: 0.040
  113. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015 Jun; 128(6):653.e7-653.e16.
    View in: PubMed
    Score: 0.038
  114. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 2015 Nov; 74(11):1968-75.
    View in: PubMed
    Score: 0.036
  115. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015 Jul; 74(7):1360-7.
    View in: PubMed
    Score: 0.036
  116. Response letter to Eltonsy and colleagues. J Am Geriatr Soc. 2013 May; 61(5):848-9.
    View in: PubMed
    Score: 0.034
  117. Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:90-8.
    View in: PubMed
    Score: 0.031
  118. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011 Dec 01; 365(22):2088-97.
    View in: PubMed
    Score: 0.030
  119. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf. 2011 Jun; 20(6):551-9.
    View in: PubMed
    Score: 0.029
  120. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
    View in: PubMed
    Score: 0.025
  121. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Am J Epidemiol. 2009 Feb 01; 169(3):273-84.
    View in: PubMed
    Score: 0.025
  122. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15; 59(8):1097-104.
    View in: PubMed
    Score: 0.024
  123. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008 Jul; 156(1):31-6.
    View in: PubMed
    Score: 0.024
  124. Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiol Drug Saf. 2008 Jun; 17(6):546-55.
    View in: PubMed
    Score: 0.024
  125. Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making. 2006 May-Jun; 26(3):247-54.
    View in: PubMed
    Score: 0.021
  126. Variable selection for propensity score models. Am J Epidemiol. 2006 Jun 15; 163(12):1149-56.
    View in: PubMed
    Score: 0.021
  127. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005 Oct; 25(5):427-34.
    View in: PubMed
    Score: 0.020
  128. Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol. 2005 Apr; 25(2):118-26.
    View in: PubMed
    Score: 0.019
  129. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004 Jul; 148(1):99-104.
    View in: PubMed
    Score: 0.018
  130. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 04; 109(17):2068-73.
    View in: PubMed
    Score: 0.018
  131. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol. 2004 Apr; 14(4):296-303.
    View in: PubMed
    Score: 0.018
  132. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15; 115(9):715-20.
    View in: PubMed
    Score: 0.018
  133. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Clin Ther. 2003 Jan; 25(1):273-84.
    View in: PubMed
    Score: 0.016
  134. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. Control Clin Trials. 2002 Dec; 23(6):757-73.
    View in: PubMed
    Score: 0.016
  135. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002 Jun; 22(3):236-43.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.